AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18034980
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate monohydrate, 50 mcg (MM)
Trial: 9927369
Drug: Inhaled lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled lidocaine
Trial: 2075140
Drug: Alugastrin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alugastrin (30 mL liquid form)
Trial: 2075140
Drug: Gastrin (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrin (tablet form)
Trial: 2075140
Drug: Wikalina (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wikalina (tablet form)
Trial: 7459426
Drug: Buffered tablet
RxNorm normalized name: CVS Aspirin 325mg Buffered Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffered tablet formulation of oxyphenbutazone
Trial: 28614691
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day)
Trial: 28614691
Drug: Itraconazole capsules
RxNorm normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole capsules (600 mg/day for 3 days, then 400 mg/day for 11 days)
Trial: 17305763
Drug: Esomeprazole 40
RxNorm normalized name: esomeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esomeprazole 40 mg once daily for 4 weeks
Trial: 19601705
Drug: Antacid use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacid use
Trial: 6104743
Drug: Prenalterol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (beta 1‐adrenoceptor agonist)
Trial: 29615092
Drug: Group-based metacognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based metacognitive therapy plus usual cardiac rehabilitation
Trial: 25275411
Drug: Preservative-free fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5%
Trial: 25275411
Drug: Preservative-free non-fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preservative-free non-fixed combination of tafluprost 0.0015% and timolol 0.5%
Trial: 21946361
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (FLX) 20 mg for 8 weeks
Trial: 18713545
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy in addition to traditional therapy
Trial: 9989194
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (21 mg/day)
Trial: 9989194
Drug: Nicotine patches
RxNorm normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches (14 mg/day)
Trial: 2152664
Drug: Iron-supplemented milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-supplemented milk (15 mg elementary iron as ferrous sulphate and 100 mg ascorbic acid per 100 g powder)
Trial: 2152664
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same milk with no supplement)
Trial: 575490
Drug: 1020 mg
RxNorm normalized name: sodium bicarbonate 1020 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1020 mg creatinol O-phosphate (group A)
Trial: 575490
Drug: 2040 mg
RxNorm normalized name: Mg
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2040 mg creatinol O-phosphate (group B)
Trial: 575490
Drug: 3060 mg
RxNorm normalized name: HOMOSALATE 3060 mg in 45 mL / OCTOCRYLENE 4500 mg in 45 mL / OCTISALATE 2250 mg in 45 mL / AVOBENZONE 1350 mg in 45 mL TOPICAL CREAM [ZO Skin Health Daily Sheer Broad-Spectrum Sunscreen SPF 50 Water Resistant (40 Minutes)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3060 mg creatinol O-phosphate (group C)
Trial: 30799646
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted therapy (TT)
Trial: 28183326
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine (IIV3) administered at day 1 and day 180
Trial: 28183326
Drug: Tetanus‐diphtheria‐pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetanus‐diphtheria‐pertussis vaccine administered at day 180
Trial: 26615504
Drug: Crestal implants
RxNorm normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crestal implants (group A)
Trial: 26615504
Drug: Subcrestal implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcrestal implants (group B)
Trial: 7882873
Drug: Standard methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard methadone maintenance therapy (comparison group)
Trial: 30132224
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of terlipressin (Group A)
Trial: 30132224
Drug: Intravenous boluses
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous boluses of terlipressin (Group B)
Trial: 30132224
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of terlipressin
Trial: 28791734
Drug: Acute alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute alcohol dose at 0.4 or 0.6 g/kg
Trial: 24056196
Drug: PD patients
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD patients OFF medication
Trial: 24056196
Drug: PD patients
RxNorm normalized name: Dianeal PD-2/2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD patients ON medication
Trial: 11239189
Drug: Psychological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy (specific details not provided)
Trial: 7965649
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (specific agents not detailed)
Trial: 27529771
Drug: 1.9-g/d n-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.9-g/d n-3 PUFA treatment
Trial: 23338733
Drug: Intra-articular lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular lidocaine injection
Trial: 21126390
Drug: Spironolactone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (1 mg/kg per day) for 7 days
Trial: 15905731
Drug: Single, dual,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, dual, and triple nucleoside reverse transcriptase inhibitors (NRTIs)
Trial: 10589441
Drug: Other commercially
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other commercially available plant preparations
Trial: 1931471
Drug: ALO1567 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALO1567 (100 mg daily)
Trial: 1931471
Drug: ALO1567 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALO1567 (200 mg daily)
Trial: 31081693
Drug: GLP‐1RA (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP‐1RA (specific drugs include liraglutide, exenatide, and lixisenatide)
Trial: 28278333
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg daily for 1 year)
Trial: 28278333
Drug: Sorafenib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (800 mg daily for 1 year)
Trial: 24461877
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Trial: 24461877
Drug: 3.6 g
RxNorm normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Trial: 26028361
Drug: 2.4 g
RxNorm normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g amino acids/(kg·d) (control group)
Trial: 19593180
Drug: Venlafaxine (VEN)
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venlafaxine (VEN) administered at daily dosages ranging from 75 to 150 mg.
Trial: 15516884
Drug: Ketamine (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.7 mg/kg)
Trial: 15516884
Drug: Tramadol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (15 mg/kg)
Trial: 8155446
Drug: Desflurane with
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane with low-dose (10 micrograms kg‐1) fentanyl
Trial: 8155446
Drug: Fentanyl (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (high-dose 50 micrograms kg‐1) with midazolam
Trial: 3412292
Drug: Intranasal pine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal pine extract (0.15 cc by metered dose spray, starting at 1/100,000 w/v, followed by 1/10,000, 1/1000 and 1/100 at 20 minute intervals)
Trial: 31064896
Drug: Indigenous Ready‐to‐use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indigenous Ready‐to‐use Therapeutic Food (Medical Nutrition Therapy)
Trial: 31064896
Drug: Standard Nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Nutrition Therapy
Trial: 28433887
Drug: Clay Art
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clay Art Therapy (CAT)
Trial: 26385052
Drug: L-arginine (6.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (6.4 g/day for 18 months)
Trial: 21559279
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) administration within three hours of injury
Trial: 19327910
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) to the head and neck
Trial: 17573455
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine
Trial: 9846910
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (5 mg at 8-h intervals for 5 days)
Trial: 8635830
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ferrous sulphate (FeSO4) tablet per day for 15 weeks
Trial: 8635830
Drug: FeSO4 tablets
RxNorm normalized name: Ferrous Sulfate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FeSO4 tablets along with 2,000,000 IU of vitamin A as single dose
Trial: 2469747
Drug: organo-heparinoid cream
RxNorm normalized name: heparinoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: organo-heparinoid cream (Hirudoid)
Trial: 31195099
Drug: Zumba exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zumba exercise for 60 minutes twice weekly for 8 weeks
Trial: 27628624
Drug: Oral Hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Hygiene Care Program (OHCP) administered twice a week for six sessions during in-hospital rehabilitation
Trial: 31912791
Drug: Vemurafenib (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (960 mg twice daily for 52 weeks)
Trial: 22089718
Drug: Evacetrapib monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib monotherapy, 30 mg/d
Trial: 22089718
Drug: Evacetrapib monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib monotherapy, 100 mg/d
Trial: 22089718
Drug: Evacetrapib monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib monotherapy, 500 mg/d
Trial: 22089718
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d) with evacetrapib, 100 mg/d
Trial: 16381016
Drug: 9 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 cycles of tailored and dose-escalated FEC (5-fluorouracil, epirubicin, cyclophosphamide)
Trial: 16381016
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of standard FEC followed by high-dose chemotherapy
Trial: 16381016
Drug: Monitoring BM
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monitoring BM changes at diagnosis and 6 months post-treatment
Trial: 16647907
Drug: Raloxifene hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride, 60 mg once daily
Trial: 16647907
Drug: Alendronate, 10
RxNorm normalized name: Alendronate, 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate, 10 mg daily
Trial: 10337502
Drug: Propionyl-L-carnitine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propionyl-L-carnitine (1 g three times a day orally for 90 days)
Trial: 7478455
Drug: Local application
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local application of tranexamic acid gel
Trial: 6957978
Drug: Pirenzepine 25
RxNorm normalized name: pirenzepine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 25 mg b.i.d.
Trial: 6957978
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg b.i.d.
Trial: 6957978
Drug: Pirenzepine 50
RxNorm normalized name: pirenzepine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine 50 mg t.d.s.
Trial: 25690514
Drug: Liberal RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liberal RBC transfusion strategy (hemoglobin <11.3 g/dL; 7 mmol/L)
Trial: 25690514
Drug: Restrictive RBC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive RBC transfusion strategy (hemoglobin <9.7 g/dL; 6 mmol/L)
Trial: 18434566
Drug: Etoricoxib 90
RxNorm normalized name: etoricoxib 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 90 mg every day
Trial: 1283476
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + galanin (500 micrograms in 100 ml saline)
Trial: 1283476
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + saline (100 ml)
Trial: 2413379
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (vinblastine 6 mg/m2 i.v., bleomycin 15 mg i.m., methotrexate 40 mg/m2 i.v., cyclophosphamide 400 mg/m2 i.v., 5-fluorouracil 5 mg/kg i.v.)
Trial: 22262728
Drug: Web-based diabetes-specific
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based diabetes-specific cognitive behavioral therapy (CBT) for depression, with minimal therapist support, delivered over 8 lessons.
Trial: 17663804
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (4.4 ml/d)
Trial: 15641055
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of disease-modifying antirheumatic drugs (DMARDs) with prednisolone
Trial: 12932590
Drug: DDDR pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDDR pacing with long AV delay (DDDR-l)
Trial: 12932590
Drug: DDDR pacing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDDR pacing (both DDDR-s and DDDR-l)
Trial: 10550443
Drug: Ibandronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (2.5 mg)
Trial: 6749526
Drug: Tolbutamide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide 0.5 g administered 30 min prior to a standardized meal
Trial: 6749526
Drug: Tolbutamide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide 0.5 g administered immediately before a standardized meal
Trial: 6749526
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered with a standardized meal
Trial: 6749526
Drug: Tolbutamide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolbutamide 0.5 g with the meal
Trial: 29945500
Drug: Non-hydroxamate HDAC6
RxNorm normalized name: Carbamyl hydroxamate
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-hydroxamate HDAC6 inhibitors identified through pharmacophore modeling and molecular docking.
Trial: 29945500
Drug: Pharmacophore model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacophore model (Hypo1) generated from 26 training set compounds.
Trial: 17973208
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus glimepiride (Group A; n=17)
Trial: 17973208
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus glimepiride and metformin (Group B; n=18)
Trial: 17973208
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin (Group C; n=17)
Trial: 16173134
Drug: Fumaria officinalis
RxNorm normalized name: Fumaria officinalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fumaria officinalis 1500 mg daily (fumitory group)
Trial: 16173134
Drug: Curcuma xanthorriza
RxNorm normalized name: Curcuma xanthorrhiza oil
DrugBank: Curcuma xanthorrhiza oil (DB11265)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuma xanthorriza 60 mg daily (curcuma group)
Trial: 11868058
Drug: tranilast (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tranilast (600 mg/day for 3 months)
Trial: 8882259
Drug: ketorolac 10
RxNorm normalized name: ketorolac 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac 10 mg
Trial: 8882259
Drug: lignocaine 10
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lignocaine 10 mg
Trial: 1948092
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg SSHA (administered daily for 11 days, with 40 mg SC administered three times every 90 min on the first day)
Trial: 1948092
Drug: 10, 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 20, 40, and 70 mg SSHA (dose-dependent effect tested)
Trial: 24994842
Drug: Standard and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard and new antiepileptic drugs (monotherapy)
Trial: 24994842
Drug: First treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First treatment failure
Trial: 22813445
Drug: Buspirone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (10 mg, 3 times daily for 4 weeks)
Trial: 21122491
Drug: 4g enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g enema administered daily (Group A, 15 pts)
Trial: 21122491
Drug: 4g enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g enema administered every 2 days (Group B, 15 pts)
Trial: 21122491
Drug: 4g enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4g enema administered every 3 days (Group C, 15 pts)
Trial: 21122491
Drug: Oral Mesalazine
RxNorm normalized name: mesalamine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Mesalazine treatment alone (OT)
Trial: 16127749
Drug: Capsaicin (1-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (1-8 microg/mL, 100 mL)
Trial: 16127749
Drug: Capsaicin (3x400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin (3x400 microg i.g. for two weeks)
Trial: 11464575
Drug: rhFSH +
RxNorm normalized name: rhTSH
DrugBank: Thyrotropin alfa (DB00024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhFSH + rhLH (group L)
Trial: 11464575
Drug: Subgroup of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup of group L (previous ART cycle with FSH only)
Trial: 5923
Drug: IV lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV lorazepam (4 mg) plus IM meperidine (50 mg)
Trial: 5923
Drug: IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV placebo plus IM meperidine (50 mg)
Trial: 6987032
Drug: Phenformin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin (50 mg)
Trial: 30208866
Drug: Durvalumab (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (5 mg)
Trial: 30208866
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg)
Trial: 30208866
Drug: Durvalumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (20 mg)
Trial: 24810796
Drug: Atropine administration
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine administration without prior oxygen
Trial: 18060379
Drug: Atropine administration
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine administration
Trial: 21945866
Drug: lipid emulsion,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lipid emulsion, LE (15 g Fabuless, containing 4.2g lipid, 0.2 MJ)+water